DBV Technologies (NASDAQ:DBVT) Shares Down 8.2% – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price was down 8.2% on Tuesday . The stock traded as low as $16.29 and last traded at $16.6360. 66,810 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 292,488 shares. The stock had previously closed at $18.12.

Analysts Set New Price Targets

DBVT has been the subject of a number of research reports. Citizens Jmp raised their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, May 1st. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Guggenheim reissued a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th. Finally, Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DBV Technologies currently has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Stock Performance

The business has a fifty day moving average of $19.19 and a 200-day moving average of $19.77. The company has a market capitalization of $920.60 million, a P/E ratio of -3.48 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.11 million. Sell-side analysts anticipate that DBV Technologies S.A. will post -0.47 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the last quarter. Truvestments Capital LLC boosted its position in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares during the last quarter. Allworth Financial LP bought a new stake in DBV Technologies during the fourth quarter worth $32,000. Royal Bank of Canada purchased a new stake in DBV Technologies in the 4th quarter valued at $34,000. Finally, Persistent Asset Partners Ltd purchased a new stake in DBV Technologies in the 4th quarter valued at $115,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.